compound semaglutide shortage Digital Health Law Firm | Nixon Law Group Compounded semaglutide: What should patients

Retrieved from NovoNordisk-a

Some providers prescribe this combination intentionally, but it requires careful monitoring

The company has an internal once-weekly peptide (NNC-06620419, Phase 2 started October 2025), a ~$2B license on United Laboratories' UBT-251 (Phase 1b/2a running, 19.7% weight loss at 24 weeks in the Chinese Phase 2), a $2.2B collaboration with Septerna for small-molecule oral GPCR agonists including a triple, and a long-running in-house discovery pipeline

There are going to be patients who need a more individualized and nuanced approach, Dr

Cardiovascular history : Patients with established cardiovascular disease may benefit from GLP-1 receptor agonists with proven cardiovascular benefits, such as semaglutide, dulaglutide, or liraglutide, which may influence medication selection and target dosing